Trista Morrison

Ception Closes $63M Series C For Anti-Inflammatory Trials

Jan. 31, 2007

By Trista Morrison

Abingworth Closes $587M Fund For Broad Range Of Investments

Jan. 30, 2007

By Trista Morrison

Abingworth Closes $587M Fund For Broad Range Of Investments

Jan. 30, 2007

By Trista Morrison

Biogen Idec Starts Phase III NHL Trial Of Galiximab Plus Rituxan

Jan. 26, 2007

By Trista Morrison

Contributing Writer

In treating cancer, two drugs often prove to be better than one. By that reasoning, Biogen Idec Inc. initiated a Phase III trial of the anti-CD80 monoclonal antibody galiximab combined with the anti-CD20 monoclonal antibody Rituxan (rituximab).

Biogen Idec Starts Phase III NHL Trial Of Galiximab Plus Rituxan

Jan. 26, 2007

By Trista Morrison

Contributing WriterIn treating cancer, two drugs often prove to be better than one. By that reasoning, Biogen Idec Inc. initiated a Phase III trial of the anti-CD80 monoclonal antibody galiximab combined with the anti-CD20 monoclonal antibody Rituxan (rituximab).